It is useful to conclude agreements on quality measures already taken daily by the oncologists of the commune and a refund can follow, said Mr. Ditarts. EAGAN, Minn. – Prime Therapeutics LLC (Prime), a leading pharmaceutical benefit (PBM), which serves more than 28 million members across the country, has entered into a value-based agreement with Pfizer Inc., a global biopharmaceutical company, to improve outcomes for patients treated for cancer. The question must be asked: does the increase in the cost of care lead to higher results? If an expensive treatment clearly gives a better result, that would be one thing. But in the opinion of payers and many oncologists, including me, this is often not the case. Often, new cancer therapies with a high price tag lead to only modest profits. Sometimes they only duplicate results seen with cheaper existing agents. Respect for evidence-based medicine and the choice of equally effective but less costly treatments will reduce the cost of cancer and achieve, or even improve, outcomes. For physicians and paying organizations, the influx of innovative therapies, especially immunotherapies, and the consequent requirement to test genetic markers increase the cost and complexity of treating patients across different types of cancers. It should come as no surprise, therefore, that payers are increasingly limiting the marketing authorization of licking drugs to the FDA label, thus limiting use outside the label. Value-based financial statements, which subordinate reimbursement to short- and long-term effectiveness, provide a unique opportunity to participate in the savings achieved through the use of online drugs and to expand access to innovative therapies to the right patients at the right time. “Data is always an important topic,” says Patrick Davish, Merck`s executive director of public affairs and policy.
Historically, he said, value-based agreements have emerged between pharmaceutical manufacturers and payers, who tend to tightly control their damage data. “We are pleased to work with Prime on this agreement using real-world data to improve patient outcomes and ultimately reduce health costs,” said Justin McCarthy, Senior Vice President, Patient and Health Impact Group, Pfizer. “By moving from a volume-based health system to a value-based health system, this collaboration is an excellent example of the partnerships we are developing across the health sector to help patients access innovative medicines.” These innovative rules are best for therapies where patient populations and clinical criteria are well defined, such as oncology. B, for which therapies have clear and measurable short- and long-term results. “An important part of Prime`s overall drug management strategy is the identification of drug treatments that, with the right measures and follow-up, can improve member outcomes and achieve the best value for patients and insurers,” said Kelly Pokuta, Vice President, Pharmaceutical Trade Relations at Prime.